Recent Updates
Recently added Catalysts
EVMN Positive Sentiment

Evommune to Present at Upcoming Investor Conferences

Monday, November 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Evommune, Inc. announced that its management will present at two upcoming investor conferences. The Stifel Healthcare Conference will feature a fireside chat on November 11, 2026, while the Jefferies Global Healthcare Conference will also include a presentation. These events aim to showcase the company's innovative therapies for chronic inflammatory diseases.

Market Sentiment Analysis

POSITIVE FACTORS

  • Evommune is actively engaging with investors.
  • Upcoming presentations may enhance visibility.
  • Management will discuss innovative therapies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+30%
120-day peak, hindsight
Typical move
12.7%
average across 3 past catalysts
Cash runway
~39 mo
Low dilution risk
Lead asset
EVO301
Phase 2 · Atopic Dermatitis (AD)

Full Press Release Details

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced presentations by management at the following upcoming investor conferences:Stifel Healthcare Conference 2026 in New York: Fireside Chat on Wednesday, November 11, 2026, at 4:40 p.m. ET.2026 Jefferies Global Healthcare Conference in London: Presentat

Frequently Asked Questions

When is Evommune's presentation at the Stifel Conference?

The presentation is on November 11, 2026, at 4:40 p.m. ET.

Where will the Jefferies Global Healthcare Conference be held?

The Jefferies Conference will take place in London.

What is the focus of Evommune's therapies?

Evommune develops therapies targeting chronic inflammatory diseases.

Who will present at the investor conferences?

Management from Evommune will lead the presentations.

ShareAdd on Google
Tags: EVMN Evommune investor conferences biotechnology chronic inflammatory diseases
Last updated: Nov 9, 2026

Biotech snapshot

Cash runway
$288M liquidity · $7M/mo burn
~39 mo
Low dilution risk
Lead asset
EVO301Phase 2
Atopic Dermatitis (AD) →

Catalyst track record

+30%
best trade around EVMN's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for EVMN.

See every catalyst's timing & PoA →